BMS-284756, a novel des-fluoro(6)-quinolone, was used to select for in vitro mutants of Staphylococcus aureus ISP794.
analyzed using the Lasergene software program. Any mutation was confirmed by sequencing an independently obtained PCR fragment. The mutant strain designation reflects the following information: mutant step, the antibiotic used for mutant selection, and the number of the mutant (Fig. 1) .
In all mutants selected by BMS-284756, for which the MIC was Ն0.06 g/ml, the GyrA 84 (Ser3Leu) mutation was present (Tables 1 and 2 ). In the case of fourth-step BMS-284756-selected mutants which had an amino acid substitution in both GyrA 84 (Ser3Leu) and GrlA 80 (Ser3Phe) (Table  1) , the ciprofloxacin MICs increased four to eightfold when the GrlA 80 (Ser3Phe) mutation was present. In contrast, the BMS-284756 MIC remained the same (Tables 1 and 2 ). To explore whether mutations outside the QRDRs might be responsible for the increased MICs for BMS-284756 fourth-step mutants, the entire gyrA/gyrB region was sequenced for two mutants. Fourth-step mutants 4(756)10-1 and 4(756)10-3 were chosen because the MIC of BMS-284756 was 1 g/ml against both strains, while ciprofloxacin, levofloxacin, and moxifloxacin MICs were two-to fourfold higher against 4(756)10-3 than against 4(756)10-1 ( Table 2 ). While both mutants had the QRDR mutation GyrA 84 (Ser3Leu), 4(756)10-3 had an additional QRDR mutation, GrlA 80 (Ser3Phe) ( Table 1 ). The only mutation identified outside the QRDRs was found in mutant 4(756)10-1 (GrlA 18 [Phe3Lys]).
Therefore, it appears that the GrlA 80 (Ser3Phe) mutation in 4(756)10-3 is sufficient to increase ciprofloxacin, levofloxacin, and moxifloxacin MICs while having no effect on BMS-284756 MICs. This may be of clinical significance, as a survey of 110 clinical isolates determined that all GyrA Ser84 mutants also had GrlA Ser80 or Glu84 mutations (7) . The lack of effect of GrlA 80 (Ser3Leu) mutations on the MIC of BMS-284756 suggests the potential of this drug to cover quinolone-resistant pathogens in the clinic.
FIG. 1. The mutant lineage of BMS-284756-selected strains is
shown. Strains in boldface were used to produce the next step mutants. 
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a FREs were determined in two separate experiments for each drug; results from both trials are shown in the two columns. b Two BMS-284756 mutants were carried forward (designated no. 6 and 10) for third-and fourth-step mutants. Each frequency was repeated twice. The first column under BMS-284756 represents mutants 6A and 6B, and the second column represents mutants 10A and 10B.
c ND, not determined.
